NOTCH1 and posterior cortical atrophy: Next generation ErbB receptor and AKT targeting agents with improved activities and hopefully fewer toxicities, and the better identification of the subsets of the PCa patients that are most likely to benefit from well-defined signal pathway modulation are necessary to successfully extend such approaches to patients with advanced and progressive PCa [65,66,67].